
## David T Miller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7688701/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies. American Journal of Human Genetics, 2010, 86, 749-764.	6.2	2,325
2	Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genetics in Medicine, 2017, 19, 249-255.	2.4	1,398
3	Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genetics in Medicine, 2019, 21, 2413-2421.	2.4	378
4	ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1381-1390.	2.4	356
5	Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1391-1398.	2.4	145
6	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848. American Journal of Human Genetics, 2018, 102, 69-87.	6.2	144
7	ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2022, 24, 1407-1414.	2.4	119
8	Insufficient Evidence for "Autism-Specific―Genes. American Journal of Human Genetics, 2020, 106, 587-595.	6.2	110
9	Chromosomal microarray testing influences medical management. Genetics in Medicine, 2011, 13, 770-776.	2.4	107
10	Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2019, 21, 769-771.	2.4	91
11	Atherosclerosis. Journal of the American College of Cardiology, 2007, 49, 1589-1599.	2.8	63
12	Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation. Genetics in Medicine, 2019, 21, 867-876.	2.4	62
13	Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 1142-1148.	2.4	59
14	Yield of additional genetic testing after chromosomal microarray for diagnosis of neurodevelopmental disability and congenital anomalies: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2018, 20, 1105-1113.	2.4	57
15	GenomeConnect: Matchmaking Between Patients, Clinical Laboratories, and Researchers to Improve Genomic Knowledge. Human Mutation, 2015, 36, 974-978.	2.5	56
16	Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. Genetics in Medicine, 2020, 22, 986-1004.	2.4	53
17	<i>BRAT1</i> mutations present with a spectrum of clinical severity. American Journal of Medical Genetics, Part A, 2016, 170, 2265-2273.	1.2	34
18	Genetics of human malignant peripheral nerve sheath tumors. Neuro-Oncology Advances, 2020, 2, i50-i61.	0.7	34

DAVID T MILLER

#	Article	IF	CITATIONS
19	A Clinician's perspective on clinical exome sequencing. Human Genetics, 2016, 135, 643-654.	3.8	33
20	Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1818-1829.	2.4	18
21	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes, 2020, 11, 387.	2.4	16
22	Genotype–phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders. Genome Medicine, 2021, 13, 90.	8.2	16
23	Growth, development, and phenotypic spectrum of individuals with deletions of 2q33.1 involving <i>SATB2</i> . Clinical Genetics, 2021, 99, 547-557.	2.0	13
24	Treating the Whole Person With Autism: The Proceedings of the Autism Speaks National Autism Conference. Current Problems in Pediatric and Adolescent Health Care, 2014, 44, 26-47.	1.7	12
25	Oligonucleotide Microarrays for Clinical Diagnosis of Copy Number Variation and Zygosity Status. Current Protocols in Human Genetics, 2012, 74, Unit8.12.	3.5	11
26	A Case of HDR Syndrome and Ichthyosis: Dual Diagnosis by Whole-Genome Sequencing of Novel Mutations in <i>GATA3</i> and <i>STS</i> Genes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 837-840.	3.6	9
27	Clinical validity assessment of genes frequently tested on intellectual disability/autism sequencing panels. Genetics in Medicine, 2022, 24, 1899-1908.	2.4	9
28	Advances in Genetic Discovery and Implications for Counseling of Patients and Families with Autism Spectrum Disorders. Current Genetic Medicine Reports, 2014, 2, 124-134.	1.9	7
29	Oligonucleotide Microarrays for Clinical Diagnosis of Copy Number Variation. Current Protocols in Human Genetics, 2008, 58, Unit 8.12.	3.5	6
30	Clinical Syndromic Phenotypes and the Potential Role of Genetics in Pulmonary Vein Stenosis. Children, 2021, 8, 128.	1.5	5
31	Genetic Testing for Developmental Delay: Keep Searching for an Answer. Clinical Chemistry, 2009, 55, 827-830.	3.2	3
32	Advances in Genetic Diagnosis of Autism Spectrum Disorders. Current Pediatrics Reports, 2014, 2, 71-81.	4.0	3
33	School liaison program supporting children with neurofibromatosis type 1: a model of care for children with chronic disease. Genetics in Medicine, 2018, 20, 785-788.	2.4	3
34	Classifying Germline Sequence Variants in the Era of Next-Generation Sequencing. Clinical Chemistry, 2016, 62, 799-806.	3.2	0
35	Response to Biesecker. Genetics in Medicine, 2017, 19, 605.	2.4	0
36	Response to Knoppers et al Genetics in Medicine, 2019, 21, 2403.	2.4	0

#	Article	IF	CITATIONS
37	Response to McGurk etÂal. Genetics in Medicine, 2021, , .	2.4	Ο